KIMS Q1 FY27 results: Revenue up 35% on consol basis, PAT falls 56%

Revenue growth above 20%EBITDA margin compressionRelated-party transactionsResults View source PDF Explain this filing

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.2%Reaction day

₹826.00

prior close

₹801.35

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%-3.3% vs market

Hospital peers, median of 26sector+0.3%-3.5% vs sector

On the reaction day the stock moved 3.3 pts less than Nifty Smallcap 250 and 3.5 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

+2.0

15m

+1.6

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.2+0.2-3.3+0.3-3.5

Next day

-3.1+0.9-4.0+0.8-3.9

-2.2+1.1-3.2+1.2-3.4

-1.3+1.0-2.4+1.4-2.7

-0.9+1.0-1.9+1.3-2.2

-1.6+1.2-2.8-0.5-1.1

-2.9+1.1-4.0-1.9-1.1

15d

-6.6+1.0-7.6-1.1-5.5

-7.8+1.7-9.6-2.9-5.0

-14.3-2.8-11.5-8.9-5.4

—————

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

KIMS reported Q1 FY27 results. Consolidated revenue rose 35% YoY to Rs 1,180 cr, but PAT fell 56% to Rs 37 cr due to higher finance and depreciation costs. Standalone revenue grew 30% to Rs 484 cr, PAT up 13% to Rs 67 cr. Company raised Rs 1,500 cr via QIP at Rs 755 per share and plans Rs 600 cr warrants to promoters. Board approved Rs 650 cr loan limit to subsidiaries and Rs 25 cr loan to material subsidiary KIMS Hospital Enterprises. S.R. Batliboi gave unmodified review opinion.

Likely market impact

Strong revenue growth but consolidated PAT under pressure from higher costs. QIP and warrant issues may dilute existing shareholders over time.